secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioXcel Therapeutics, Inc. (BTAI)
CIK:        0001720893
Form:       8-K
Filed at:   2024-11-25T23:59:59+00:00
Accession:  0001104659-24-122587
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioXcel raises ~$6.2M in public offering of stock and warrants; cash runway into Q1 2025
--------------------------------------------------------------------------------

- Issued 5.6M shares and warrants, plus 9M pre-funded warrants, at $0.48 per share (or $0.479 for pre-funded).
- Net proceeds of ~$6.2M after underwriting discounts; use for SERENITY At-Home and TRANQUILITY In-Care trials.
- Cash runway expected into Q1 2025 when combined with existing cash; potential need for additional capital.
- Exercise price of 8.5M previously issued warrants reduced to $0.571 per share on Nov 21, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720893/000110465924122587/0001104659-24-122587-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720893/000110465924122587/tm2428677d4_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-122587

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer